Differentiation of benign and malignant breast tumors by in-vivo three-dimensional parallel-plate diffuse optical tomography

Regine Choe  
Soren D. Konecky  
Alper Corlu  
University of Pennsylvania  
Department of Physics & Astronomy  
209 S. 33rd Street  
Philadelphia, Pennsylvania 19104  
E-mail: rgchoe@alumni.upenn.edu

Kijoon Lee  
Nanyang Technological University  
School of Chemical and Biomedical Engineering  
Division of Bioengineering  
Singapore 637457  
and  
University of Pennsylvania  
Department of Physics & Astronomy  
209 S. 33rd Street  
Philadelphia, Pennsylvania 19104

Turgut Durduran  
University of Pennsylvania  
Department of Physics & Astronomy  
209 S. 33rd Street  
Philadelphia, Pennsylvania 19104  
and  
Hospital of the University of Pennsylvania  
Department of Radiology  
3400 Spruce Street  
Philadelphia, Pennsylvania 19104

David R. Busch  
Saurav Pathak  
University of Pennsylvania  
Department of Physics & Astronomy  
209 S. 33rd Street  
Philadelphia, Pennsylvania 19104

Brian J. Czerniecki  
Julia Tchou  
Douglas L. Fraker  
Hospital of the University of Pennsylvania  
Department of Surgery  
3400 Spruce Street  
Philadelphia, Pennsylvania 19104

Angela DeMichele  
Hospital of the University of Pennsylvania  
Department of Medicine (Hematology/Oncology)  
3400 Spruce Street  
Philadelphia, Pennsylvania 19104

Britton Chance  
University of Pennsylvania  
Department of Biochemistry & Biophysics  
3700 Hamilton Walk  
Philadelphia, Pennsylvania 19104

Simon R. Arridge  
Martin Schweiger  
University College London  
Department of Biochemical Engineering  
Gower Street  
London, WC1E 6BT  
United Kingdom

Joseph P. Culver  
University of California  
Department of Medicine  
School of Medicine  
Mallinckrodt Institute of Radiology  
St. Louis, Missouri 63110  
and  
University of Pennsylvania  
Department of Physics & Astronomy  
209 S. 33rd Street  
Philadelphia, Pennsylvania 19104

Mitchell D. Schnall  
Hospital of the University of Pennsylvania  
Department of Radiology  
3400 Spruce Street  
Philadelphia, Pennsylvania 19104

Mary E. Putt  
University of Pennsylvania  
Department of Biostatistics & Epidemiology  
423 Guardian Drive  
Philadelphia, Pennsylvania 19104

Mark A. Rosen  
Hospital of the University of Pennsylvania  
Department of Radiology  
3400 Spruce Street  
Philadelphia, Pennsylvania 19104

Arjun G. Yodh  
University of Pennsylvania  
Department of Physics & Astronomy  
209 S. 33rd Street  
Philadelphia, Pennsylvania 19104

Address all correspondence to Regine Choe, Department of Physics and Astronomy, University of Pennsylvania, 209 S. 33rd St., Philadelphia, PA, 19104. E-mail: rgchoe@alumni.upenn.edu

1083-3668/2009/14(2)/024020/18/$25.00 © 2009 SPIE

Journal of Biomedical Optics 14(2), 024020 (March/April 2009)
Abstract. We have developed a novel parallel-plate diffuse optical tomography (DOT) system for three-dimensional in vivo imaging of human breast tumor based on large optical data sets. Images of oxy-, deoxy-, and total hemoglobin concentration as well as blood oxygen saturation and tissue scattering were reconstructed. Tumor margins were derived using the optical data with guidance from radiology reports and magnetic resonance imaging. Tumor-to-normal ratios of these endogenous physiological parameters and an optical index were computed for 51 biopsy-proven lesions from 47 subjects. Malignant cancers (N=41) showed statistically significant higher total hemoglobin, oxy-hemoglobin concentration, and scattering compared to normal tissue. Furthermore, malignant lesions exhibited a twofold average increase in optical index. The influence of core biopsy on DOT results was also explored; the difference between the malignant group measured before core biopsy and the group measured more than 1 week after core biopsy was not significant. Benign tumors (N=10) did not exhibit statistical significance in the tumor-to-normal ratios of any parameter. Optical index and tumor-to-normal ratios of total hemoglobin, oxy-hemoglobin concentration, and scattering exhibited high area under the receiver operating characteristic values from 0.90 to 0.99, suggesting good discriminatory power. The data demonstrate that benign and malignant lesions can be distinguished by quantitative three-dimensional DOT. © 2009 Society of Photo-Optical Instrumentation Engineers. [DOI: 10.1117/1.3103325]

Keywords: breast cancer; diffuse optical tomography; near-infrared light; photon migration; optical mammography.

Paper 083428 received Sep. 23, 2008; revised manuscript received Jan. 22, 2009; accepted for publication Jan. 23, 2009; published online Apr. 14, 2009.

1 Introduction

Breast cancer is one of the most common cancers among women. Approximately one in eight women in the United States will develop breast cancer during their lifetime, and of these, about 20–30% will ultimately die of the disease.1 Thus, early detection and accurate diagnosis of breast cancer are important. Existing clinical methods used for breast cancer screening and diagnosis, however, have drawbacks. X-ray mammography, for example, has an ~22% false-negative rate in women under 502 and sometimes cannot accurately distinguish between benign and malignant tumors.3 Even though the false-positive rate of individual mammography is less than 10%,4 18% of women with no breast cancer will undergo a biopsy after 10 mammograms.5 Techniques such as ultrasound and magnetic resonance imaging (MRI) are sometimes used in addition to X-ray mammography, but they have limitations such as high cost, low throughput, limited specificity (MRI), and low sensitivity (ultrasound). Thus, new methods are needed to detect cancers earlier for treatment, to detect cancers missed by mammography,6–8 to reduce the false-positive rate,9,10 and to monitor tumor progression during cancer therapy.

Near-infrared (NIR) diffuse optical tomography (DOT) and spectroscopy (DOS) are tools that rely on functional processes for contrast and therefore have the potential to enhance sensitivity and specificity of breast cancer detection/diagnosis. DOT and DOS utilize nonionizing, low-power NIR light and are noninvasive and rapid. These diffuse optical methods measure wavelength-dependent tissue optical absorption coefficients, which in turn provide access to blood dynamics, total hemoglobin concentration (THC), tissue blood oxygen saturation (SO2), and concentrations of water and lipid. Tissue properties accessible to DOT and DOS techniques have been demonstrably different in tumors compared to normal tissues.9–20 The microscopic origin of tumor optical absorption contrast has been partially explored through the positive correlation of microvessel density and total hemoglobin concentration.13,17,28 Similarly, mean size and volume fraction of the nucleus and nucleolus measured by microscopy have been correlated with light scattering measured by DOT.29 The optical contrast in rapidly growing tumors is physiologically plausible, because these tissues often exhibit increased vascularity, altered oxygen content, and altered cellular structures at the microscopic scale.30–32 Finally, DOT and DOS are attractive for applications such as cancer therapy that require frequent monitoring of physiological parameters. Thus far, changes in tumor contrast during therapy have exhibited agreement with physiological expectations13,14,18,26 and with observations made by other imaging modalities.19,27,37–39

To date, optical data from sizable numbers of tumors (i.e., more than 30 tumors) have been reported by several research groups.25–26,40,41 These results generally indicate that optical methods are capable of distinguishing lesions from healthy background tissue.42 Demonstrations of a clear distinction between benign and malignant tumors, however, have been scarce, either due to a lack of benign lesion data25,40 or to a limited three-dimensional (3-D) imaging capability.23,24 Even the systems geared towards 3-D image reconstructions26,41 have not as yet explored the full capability of diffuse optical tomography. Better characterization of malignant and benign lesions is anticipated through improvements in spatial resolution of instrumentation and reconstruction algorithms, and also through an increase in spectral information.43 In order to improve the spatial resolution, for example, the number of source and detector positions covering the whole breast should be very large.43 DOT also relies heavily on reconstruction algorithm quality for accurate quantification of optical properties; optimization of such algorithms is still an open arena for further development and is a key factor for improved image fidelity.

In this contribution, we report tumor contrast extracted from 3-D reconstructions of 51 breast tumors acquired using a parallel-plate DOT system. In addition to measurement geometry, our approach differs from others as a result of its very large data-set size with on- and off-axis measurements for full 3-D reconstruction and its highly optimized reconstruction schemes. The reconstruction algorithm employs iterative nonlinear methods for accuracy, multispectral data for reliable determination of chromophore concentrations and scattering parameters, parallel computing for speed, and spatially variant regularization for image artifact suppression. Furthermore, in order to avoid complications from image artifacts and lack of optical contrast in some lesions, in this study we have used information from dynamic contrast-enhanced MRI (DCE-MRI) to confirm and assign tumor margins. In total, these strategies improve the extraction of tumor-to-normal optical
contrast from 3-D oxy-hemoglobin, deoxy-hemoglobin, and scattering DOT images.

Briefly, malignant cancer showed statistically significant higher total hemoglobin concentration and scattering compared to normal tissue, with a twofold average increase in an optical index derived from intrinsic optical parameters. We did not observe statistically significant differences due to core biopsy in the malignant cancer group; potential bleeding due to core biopsy did not influence DOT results for those measured more than 1 week after core biopsy. Total hemoglobin concentration, blood oxygenation, and scattering were distinguishably lower in a cyst, whereas the difference between tumor and normal tissues for a fibroadenoma and a lobular carcinoma in situ were not apparent. Among many parameters, tumor-to-normal ratios of total hemoglobin concentration, scattering, oxy-hemoglobin concentration and the optical index demonstrated values of the AUC [area under the receiver operating characteristic (ROC) curve] higher than 0.9, suggesting good discriminatory power for resolving malignant from benign lesions.

The remainder of this paper is organized as follows. The Methods section provides demographic and histopathologic information about the subjects; it also describes the DOT instrument, the human subject measurement protocol, 3-D image reconstruction procedures, procedures for tumor-to-normal DOT parameters extraction, and statistical analysis. The Results section presents the data and demonstrates a correlation between DOT and DCE-MRI images using a representative case for each lesion type. This section also presents a comparison of tumor-to-normal DOT parameters among benign, malignant, and biopsied malignant groups. The Discussion section critiques our analysis method, compares results with other DOT/DOS studies, and gives suggestions for future improvements. In addition, supplementary material (Appendix) about measurement and analysis details are provided with the paper.

2 Methods

2.1 DOT Instrumentation

Our parallel-plate DOT system has been characterized using tissue phantoms simulating the breast with tumors. The system consists of a light-source module, a table with a built-in Intralipid/Ink fluid tank (i.e., the “breast box”), and a detection module. The light-source module is comprised of laser diodes, optical switches and optical fibers. Six NIR laser diodes are connected to a 6 × 1 optical switch, which in turn is connected to a 1 × 45 optical switch. The 45 optical fibers from this switch are arranged on a 9 × 5 grid pattern at the compression plate as seen in Fig. 1. Of the six lasers, four (690, 750, 786, and 830 nm) are sinusoidally intensity modulated at 70 MHz for frequency-domain measurements. Out of 47 patients, the first 15 patients were measured using this laser configuration (four wavelengths). Later, 11 patients were measured with an additional continuous-wave laser at 650 nm, and 23 patients were measured with continuous-wave lasers at 650 and 905 nm. These additional lasers were added to improve separation of chromophore contributions based on findings in Refs. 45 and 46.

Subjects lie in a prone position on the table with breasts positioned inside the breast box, which contains an Intralipid/Ink fluid whose optical properties are similar to breast tissue ($
\mu_s=0.05 \text{ cm}^{-1}$ and $
\mu_s'=8 \text{ cm}^{-1}$ at 786 nm). The fluid is made with an Intralipid scattering agent and an India ink absorption agent. The breast box is made of black-pigment coated aluminum, with one side replaced by an antireflection coated plexiglass viewing window.

The compression plate also contains nine optical fibers in a 3 × 3 grid for frequency-domain detection. The detection has two measurement modes: a remission frequency-domain measurement mode and a transmission continuous-wave measurement mode. The frequency-domain measurements utilize homodyne techniques to provide an initial estimate of breast bulk optical properties for image reconstruction. Transmission continuous-wave data at the viewing window are collected by a lens-coupled 16-bit charge-coupled-device (CCD) camera.

Our DOT instrumentation was designed to provide the large data sets essential for full 3-D reconstruction. The lens-coupled CCD in our system contains the largest number of on-axis and off-axis measurements covering the whole breast among 3-D DOT instruments. For example, even instruments geared toward 3-D reconstruction typically have up to $\sim 10^3$ source–detector pairs, whereas our instrument utilizes $4 \times 10^4$ source–detector pairs per wavelength for reconstruction. The direct use of a lens-coupled CCD, as opposed to fiber coupling, greatly reduces the calibration coefficient unknowns. The parallel-plate transmission geometry with soft compression provides increased light transmission and reduced-detection dynamic-range linearity requirements compared to other geometries, e.g., the uncompressed conical or ring geometry. The use of Intralipid/Ink fluids further reduces dynamic-range requirements and ensures good contact between optodes (sources and detectors) and the diffuse medium (i.e., the breast and Intralipid/Ink fluid). Finally, our hybrid system permits measurement of bulk optical prop-

![Fig. 1 Schematic of the parallel plate diffuse optical tomography instrument. A female subject lies in prone position on a bed with her breasts inside the breast box filled with an Intralipid/Ink fluid. Continuous-wave transmission and frequency-domain remission measurements are performed simultaneously by a CCD camera and nine Avalanche Photodiodes connected by fibers on the source plate for 45 source positions at multiple wavelengths.](https://www.spiedigitallibrary.org/journals/Journal-of-Biomedical-Optics/2009/L50098-Vol.14/24020-3)
properties for use as initial guess in our reconstruction. Pure continuous-wave measurement systems do not have this capability.

2.2 DOT Measurement Protocol

All human research was approved by the University of Pennsylvania Institutional Review Board. Informed consent was obtained from each subject. Then, the subject was positioned on the table with both breasts inside the empty breast box. Based on the tumor location identified by palpation or prior radiological information, the breast position with respect to the viewing window was optimized such that the tumor was well within the field of view. Then, a soft compression was applied to hold the breast in a stable position. The compression distance varied between 5.5 and 7.5 cm (6.4 ± 0.5 cm), depending on the breast size. A snapshot of the breast outline was taken by the CCD camera before filling the box with the Intralipid/Ink fluid. After filling the box, the diffuse optical image scan was conducted for 8–12 min. Typically, we only measured a single breast per subject, most often with a single lesion. After the subject measurements, we filled the breast box completely with Intralipid/Ink fluid and covered the top of the box with a slab of silicone phantom to take reference optical measurements. The silicone slab extends the diffuse medium vertically above the breast box, just as the subject’s torso extends the diffuse medium in the actual breast measurement.

2.3 3-D DOT Reconstruction

The NIR spectra of major tissue chromophores, such as oxygenated hemoglobin (HbO2), deoxygenated hemoglobin (Hb), water, and lipid, are well-known, and imaging is readily possible because their NIR absorptions are much lower than in visible or infrared spectral regions. The overall tissue absorption coefficient, μa, at a given wavelength (λ) may be decomposed into linear contributions from major chromophores via the relation μa(λ) = \sum_{l=1}^{L} \epsilon_l(λ)C_l + \mu_{bg}^a(λ), where L is the total number of chromophores, \epsilon_l(λ) is the extinction coefficient of the lth chromophore, C_l is the concentration of lth chromophore, and \mu_{bg}^a(λ) is a background absorption coefficient. The scattering coefficient is significantly larger than the absorption coefficient in the NIR, so that the propagation of light is well-modeled by the photon-diffusion equation. The spectral variation of the reduced scattering coefficient is further approximated to have the form, μs(λ) = \Delta λ/\lambda^b, a result based on simplified Mie scattering theory. Here, A is the scattering prefactor and \lambda is the scattering power, which depends on the size and number of the scatterers in the tissue. The multispectral method utilizes these spectral relations as constraints, using all wavelength data simultaneously to fit for chromophore concentrations and scattering factors directly, rather than first fitting \mu_a and \mu_s individually for each λ and then subsequently calculating concentrations from.

Using this multispectral method, we derived average bulk optical properties of breast based on remission frequency-domain measurements by fitting C_{Hb}^b (breast), C_{HbO2}^b (breast), \epsilon_{Hb}^b (breast), and \epsilon_{HbO2}^b (breast) using an analytic solution of photon-diffusion for a semi-infinite medium. \mu_{bg}^a(λ) of breast was fixed as a combination of 31% water and 57% lipid absorption based on the literature. Intralipid/Ink fluid properties C_{Hb}^b, A_{Hb}^b (Intralipid), and \epsilon_{HbO2}^b (Intralipid) were derived from frequency-domain reference measurements made on the breast box when it was completely filled with an Intralipid/Ink solution. Then, we applied the multispectral approach to enhance image reconstruction by reducing the number of unknowns compared to the available measurements. This approach enables us to achieve reasonable separation between absorption and scattering even for continuous-wave measurements. The unknowns for reconstruction were C_{Hb}(r), C_{HbO2}(r), and A(r), where r represents position within the 3-D sample volume. To assess the initial values for these parameters, we segmented the reconstruction volume into a half-ellipsoidal breast region and an Intralipid/Ink fluid region based on the breast outline photo. Then, initial values for the parameters C_{Hb}(r) and C_{HbO2}(r) were assigned to C_{Hb}^b (breast) and C_{HbO2}^b (breast) if r falls into the breast region or to zero otherwise. Initial values for A(r) were set to A_{Hb}^b (breast) if r falls into the breast region or A_{Hb}^b (Intralipid) if it falls into Intralipid/Ink fluid region. \mu_{bg}^b of the Intralipid/Ink fluid region was fixed by the directly measured \mu_{bg} of the fluid through C_{HbO2}^b. The scattering power was fixed as \mu_{HbO2} (breast) and \mu_{Hb} (Intralipid) for each region, respectively.

For the given set of optical properties, a finite-element method based numerical solver was utilized to derive a calculated fluence rate, \Phi_m(r_d) at detector position r_d, given a set of optical properties. To suppress image artifacts associated with sources and detectors, we used a nonuniform, unstructured mesh with higher nodal concentrations at source/detector planes for the finite-element method. The measured fluence rate, \Phi_m(r_d), was constructed by down-sampling and smoothing the CCD data on a 41 × 24 grid (as shown in Fig. 1) corresponding to a 3 mm spacing for each detector. We defined a Rytov-type objective function χ^2 with the Intralipid/Ink fluid reference measurements used for normalization (the specific form of χ^2 is given in Ref. 19 and in the Appendix). The unknowns were updated using an iterative conjugate-gradient-based scheme modified to include the multispectral approach. The iterative nonlinear method is superior to linear methods for quantification, because the inverse problem is intrinsically nonlinear. The memory-efficient conjugate gradient method allowed use of large data sets (10^4 spatial × 6 spectral data). Furthermore, parallel computation was implemented to dramatically speed up reconstruction time.

In order to compensate for higher sensitivity near source/detector planes and lower sensitivity near the sample center, spatially variant regularization was added within the objective function. To find an optimum regularization parameter, α, an initial reconstruction using an envelope-guided regularization technique was performed, first yielding an estimate of the initial regularization parameter, \alpha_0. Then, nine reconstructions were performed with nine different regularization parameters ranging from 0.01 \alpha_0 to 100\alpha_0 to further optimize this parameter. We examined the L curve that plots the residual norm (i.e., the sum squared difference between measured and calculated data) versus the image norm (i.e., the sum squared difference between the initial guess and recon-
structed optical parameters) to find the optimal regularization parameter.

After the selection of the best $C_{\text{HbO}_2}(r)$, $C_{\text{Hb}}(r)$, and $A(r)$ images based on the optimal regularization parameter determined by the $L$-curve analysis, we constructed 3D images of total hemoglobin concentration $[\text{THC}(r)]=C_{\text{HbO}_2}(r)+C_{\text{Hb}}(r)$, blood oxygen saturation $[\text{StO}_2(r)]=C_{\text{HbO}_2}(r)/\text{THC}(r)$, scattering $\mu_s^r(\mathbf{r},\lambda)=A(r)\lambda^{-\sigma^r(r)}$, and the overall optical attenuation $\mu^\text{eff}(r)=\sqrt[3]{\mu_s^r(\mathbf{r})\mu^a(\mathbf{r})}$ at 786 nm.

### 2.4 Extraction of DOT Tumor Parameters

In order to extract DOT parameters from tumor and healthy regions, additional steps were taken. First, the approximate tumor location was determined based on MR images of the same breast. Each tumor was classified as belonging to the retroareolar region or one of four quadrants (i.e., upper outer, upper inner, lower inner, and lower outer quadrant). The relative proximity of the mass with respect to the nipple and the chest wall was also noted. When MRI was not available, spatial information about the tumor was derived from radiology reports based on X-ray mammograms and ultrasound. Then, based on the outline photo of the breast, we determined the position of the nipple in the DOT images and then in the corresponding axial DOT slices. We chose to use a $\mu^\text{eff}$ at 786 nm map for tumor segmentation, as it represents a combination of absorption and scattering contrast and, therefore, is less sensitive to parameter cross-talk.

The spatial location with maximum intensity of $\mu^\text{eff}$ at 786 nm near the radiologically determined tumor region was marked as the starting point for a 3-D region growing algorithm, with cutoff at full-width-at-half-maximum. When the tumor-to-normal contrast was relatively low, such that the region grew into multiple locations, tumor size extracted either from pathology or radiology reports was used as a limiting factor to stop the growth algorithm. This approach was effective for selection of tumor regions in images while minimizing the influence of artifacts. Because our DOT reconstructions are subject to source and/or detector artifacts, slices near the source and detector planes (up to 8 mm) were excluded from the region-growing process. When the tumor was not adequately visible in DOT [e.g., in some fibroadenomas ($N=3$), lobular carcinomas in situ ($N=2$), and fibrocytic lesions ($N=1$)], then the region was fixed based on radiological assessment rather than the region-growing algorithm. Normal tissue was defined as the breast tissue outside the tumor region based on the following criteria: (i) slices up to 8 mm from source and detector planes were excluded and (ii) regions with $\mu^\text{eff}$ at 786 nm outside plus/minus two standard deviations from its average over the entire breast were excluded. These exclusions ensured that source and detector artifacts were removed from the “average” normal tissue. Factors such as different compression schemes and shifts of nipple location due to breast-positioning variation were necessarily considered, because the breast is a highly deformable organ. MRI, for example, used sagittal compression for breast imaging, whereas DOT used axial compression in this study. We averaged the DOT parameters inside the regions defined by the above segmentation (i.e., to obtain mean $\bar{X}_T$ for the tumor region and mean $\bar{X}_N$ for the normal region, where $X$ is the optically derived physiological variable). An optical contrast ratio (i.e., $X_T/X_N$, the relative value of $X$ between the tumor and normal tissue) was then defined as in Table 1. We also defined an optical index $\text{OI}=r\text{THC} \times r\mu^a/r\text{StO}_2$. The rationale for this index was based on the hypothesis that tumor THC and scattering increase due to increased angiogenesis and cell proliferation, while StO$_2$ decreases due to hypermetabolism. Images of relative values of any variable are defined in a similar fashion: $rX=\bar{X}_T/\bar{X}_N$ and $\text{OI}(\mathbf{r})=r\text{THC}(\mathbf{r}) \times r\mu^a(\mathbf{r})/r\text{StO}_2(\mathbf{r})$.

### 2.5 Classification of Groups

Only the biopsy-proven lesions from the histopathology report were selected for quantification of optical tumor-to-normal contrast. Lesions were separated into three groups: benign (all benign lesions were measured by DOT before core biopsy), malignant lesions measured before core biopsy (M-Bcb), and malignant lesions measured after core biopsy (M-Acb). The separation of malignant lesions into pre- and post-core biopsy groups enabled us to address the concern that bleeding induced by core biopsy might influence DOT. Subjects who had fine needle aspiration prior to DOT measurements were included in the pre-core biopsy group (i.e., M-Bcb group), because the fine needle aspiration was deemed to have minimal effect. For the M-Acb group, the DOT measurement was carried out more than 1 week after core biopsy, ensuring some level of healing.

From demographic information, parameters such as age, height, weight, menopausal status, and race were also collected. Body mass index (BMI) was calculated as $\text{BMI} = \text{weight}/\text{height}^2$ (in kilograms per meters squared). From the pathology reports, in addition to lesion type, lesion size and modified Bloom and Richardson scores (mBR) were extracted. When the lesion size was not available or was ambiguous in the pathology report, the longest dimension of the

### Table 1 Definition of extracted optical parameters from DOT images.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Relative total hemoglobin concentration</td>
<td>$r\text{THC}$</td>
<td>$\text{THC}_T/\text{THC}_N$</td>
</tr>
<tr>
<td>Relative blood oxygen saturation</td>
<td>$r\text{StO}_2$</td>
<td>$\text{StO}_2(T)/\text{StO}_2(N)$</td>
</tr>
<tr>
<td>Relative deoxy-hemoglobin concentration</td>
<td>$r\mathrm{Hb}$</td>
<td>$\bar{\mathrm{Hb}}_T/\bar{\mathrm{Hb}}_N$</td>
</tr>
<tr>
<td>Relative oxy-hemoglobin concentration</td>
<td>$r\mathrm{HbO}_2$</td>
<td>$\bar{\mathrm{HbO}}_2(T)/\bar{\mathrm{HbO}}_2(N)$</td>
</tr>
<tr>
<td>Relative scattering coefficient (786 nm)</td>
<td>$r\mu^a$</td>
<td>$\bar{\mu}^a_T/\bar{\mu}^a_N$</td>
</tr>
<tr>
<td>Optical index</td>
<td>OI</td>
<td>$r\text{THC} \times r\mu^a/r\text{StO}_2$ (T): tumor, (N): normal</td>
</tr>
</tbody>
</table>

---

Journal of Biomedical Optics 024020-5 March/April 2009 • Vol. 14(2)
lesion was extracted from the radiology report and was taken as the lesion size. Mammographic density information was collected from the radiology reports.

### 2.6 Statistical Analysis

Statistical analysis of these data was performed using R 2.6, a statistical computing and graphics software. A type I error rate of 0.05 was used for all hypothesis tests. Demographic data were summarized using means and 95% confidence intervals (CIs) for continuous data or percentages for categorical data.

The optical tumor contrast ratios were log-transformed to achieve approximate normality and then analyzed using a mixed-effects model. In this model, we took into account the potential correlation between measurements taken from multiple lesions in the same breast or in the same women. We fit to a model that estimated the mean optical contrast ratio for each group. After developing 95% CIs using the resulting standard errors, we tested the hypothesis that each optical contrast parameter was unity. Because the bleeding induced by a core biopsy might be expected to influence DOT results, for the malignant group we tested the hypothesis that there were no differences in mean optical contrast ratio associated with receiving/not receiving a core biopsy. Also, we tested another null hypothesis that there were no differences in mean optical contrast ratios between benign and malignant groups. Finally, we used univariate models to test whether there was an association between optical tumor contrast ratios and clinical covariates including BMI, menopausal status, lesion size, and race. For any variable that showed a significant univariate association, we tested whether the association persisted in a model that also included lesion pathology (i.e., benign or malignant).

Lastly, to assess the capacity of the approach to discriminate between benign and malignant lesions, we constructed logistic regression models using each optical parameter as the predictor in the model. Odds ratios (ORs) were used to estimate the effect sizes, the significance of each effect was assessed using a Wald test, and an ROC curve was constructed using the estimates of sensitivity and specificity. An AUC was calculated for each DOT parameter to serve as a measure of discrimination. Because logistic regression assumes that observations are independent, we carried out a sensitivity analysis using a subset of the data where the malignant lesions from two women with a benign lesion were dropped, and where one malignant lesion was dropped from each of the two women with two malignant lesions. This modification to the data set had negligible impact on the findings presented here. Representative error estimates for sensitivity and specificity were computed using the exact binomial distribution.

### 3 Results

#### 3.1 Demographic, Radiologic, and Histopathologic Information of Benign and Malignant Lesions

We recruited 60 female subjects for DOT measurement between the years 2001 and 2006. All of these subjects had a clinically suspicious lesion. Subjects with prior mass-removal surgery (N=4) or subjects undergoing neoadjuvant chemotherapy (N=2) were not included in the analysis. Thus, only properties of lesions prior to clinical intervention were probed. Subjects with breast implants (N=1) or with extensive bleeding due to previous core biopsy (N=2) were also excluded from the analysis, because these conditions significantly affected DOT signal-to-noise. Subjects with no biopsy results (N=4) were excluded as well. We report on DOT measurements and analyses of 47 female subjects with biopsy-proven lesions.

Fifty-one lesions from 47 patients were characterized with DOT. Ten patients had benign lesions, and of these, two patients had an additional malignant lesion. In Table 2, these patients were assigned to the benign group. A total of 37 patients had exclusively malignant lesions, and of these, two patients had two lesions. No patient had more than two lesions. The demographic information for patients in benign and malignant groups is presented in Table 2. Average lesion size along the longest dimension was 1.8 cm for benign and 2.1 cm for malignant lesions, ranging from 0.4 to 9.3 cm. The majority of women in this study were premenopausal (60% of benign group, 51% of malignant group) and Caucasians (>65% both groups) with mean ages of 43 (benign group) to 48 (malignant group). At least half of both groups

### Table 2 Clinical characteristics of subjects, categorized by benign or malignant lesions. For continuous data such as age, mean±standard deviations are shown. For each categorical variable, the number of women in the group appears in parentheses.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Subjects with benign lesions (n=10)</th>
<th>Subjects with malignant lesions (n=37)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yr)</td>
<td>43±11</td>
<td>48±11</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>26±5</td>
<td>27±6</td>
</tr>
<tr>
<td>Menopausal status</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Premenopausal</td>
<td>6 (60%)</td>
<td>19 (51%)</td>
</tr>
<tr>
<td>Postmenopausal</td>
<td>4 (40%)</td>
<td>18 (49%)</td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td>7 (70%)</td>
<td>29 (78%)</td>
</tr>
<tr>
<td>African American</td>
<td>1 (10%)</td>
<td>6 (16%)</td>
</tr>
<tr>
<td>Asian</td>
<td>1 (10%)</td>
<td>1 (3%)</td>
</tr>
<tr>
<td>Hispanic</td>
<td>1 (10%)</td>
<td>1 (3%)</td>
</tr>
<tr>
<td>Mammographic density</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Almost entirely fat</td>
<td>1 (10%)</td>
<td>2 (5%)</td>
</tr>
<tr>
<td>Scattered fibroglandular densities</td>
<td>3 (30%)</td>
<td>9 (24%)</td>
</tr>
<tr>
<td>Heterogeneously dense</td>
<td>3 (30%)</td>
<td>20 (54%)</td>
</tr>
<tr>
<td>Extremely dense</td>
<td>1 (10%)</td>
<td>1 (3%)</td>
</tr>
<tr>
<td>Unknown</td>
<td>2 (20%)</td>
<td>5 (14%)</td>
</tr>
<tr>
<td>Lesion size (cm)</td>
<td>1.8±1.7</td>
<td>2.1±1.2</td>
</tr>
</tbody>
</table>
with known mammographic density had heterogeneously
dense or extremely dense breasts as determined by X-ray mammography.

The histopathologic diagnosis of these lesions is summarized in Table 3. We divided the 51 lesions into three groups: (i) benign, (ii) MalBeb, and (iii) MalAbc. 80 and 95% of the malignant lesions measured before and after core biopsy in this study were invasive ductal carcinoma, while 40% of the benign lesions were fibroadenomas, 30% were cysts, 30% were lobular carcinoma in situ, and 10% were fibrocystic disease.

### Table 3  Pathologic characteristics of 51 lesions measured with DOT before or after core biopsy.

<table>
<thead>
<tr>
<th>Histopathologic diagnosis</th>
<th>Number of lesions measured by DOT before core biopsy (n=30)</th>
<th>Number of lesions measured by DOT after core biopsy (n=21)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Malignant (n=41)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Invasive ductal carcinoma</td>
<td>16</td>
<td>20</td>
</tr>
<tr>
<td>Invasive lobular carcinoma</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Ductal carcinoma in situ</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Benign (n=10)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fibroadenoma</td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td>Cyst</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Fibrocystic</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Lobular carcinoma in situ</td>
<td>2</td>
<td>0</td>
</tr>
</tbody>
</table>

The second example is from a 39-year-old premenopausal female with a mixture of ductal carcinoma in situ and lobular carcinoma in situ in her left breast. X-ray mammography and ultrasound detected a 3-cm mass at 3 o’clock. In DCE-MRI, enhancement spanning 3–5 cm appeared around 3–4 o’clock, which corresponds to left upper side of the axial image as shown in Fig. 3(b). DOT measurements were performed before core biopsy. The mammographic density of this breast fell into the scattered fibroglandular category. Histopathology analysis after mastectomy revealed a 2.0-cm mixture of invasive ductal carcinoma (with mBR grade of 8) and ductal carcinoma in situ behind the nipple.

The compression distance for the DOT measurement of the same subject was 6 cm. The nipple was shifted toward the source plane during DOT positioning; thus, the slice best exhibiting the tumor contrast turned out to be the one 1.8 cm away from the source plane. As can be seen in Fig. 2, DOT slices showed elevated \( r_{\text{THC}} \), \( r_{\mu_0} \), \( r_{\text{HbO}_2} \), \( r_{\text{Hb}} \), and OI at the tumor site, slightly displaced toward the lateral side (i.e., the right side of the axial image for right breast), in agreement with the MRI axial slice. The \( r_{\text{SKO}_2} \) slice did not exhibit a localized feature, but rather it showed a broad, slightly low oxygenation region near the tumor location. While elevated values of most parameters were apparent within the tumor site, subtle differences in the images were always found.

#### 3.2.2 Ductal and lobular carcinoma in situ

The second example is from a 39-year-old premenopausal female with a mixture of ductal carcinoma in situ and lobular carcinoma in situ in her left breast. X-ray mammography and ultrasound detected a 3-cm mass at 3 o’clock. In DCE-MRI, enhancement spanning 3–5 cm appeared around 3–4 o’clock, which corresponds to left upper side of the axial image as shown in Fig. 3(b). DOT measurements were performed before core biopsy. The mammographic density of this breast fell into the extremely dense category. Histopathology analysis of the excisional biopsy sample revealed an extensive ductal carcinoma in situ, with intermediate-grade nuclei growing in a solid pattern with focal comedo-type necrosis and extensive lobular carcinoma in situ.

The compression distance for the DOT measurement was 6 cm. The nipple was shifted toward the detector plane during DOT positioning; thus, the slice at 4.6 cm from the source plane was selected for presentation. In the reconstructed im-
Fig. 3, three regions with elevated contrast in rTHC and rHb are evident. However, the contrast of each region is much lower than those of the invasive carcinoma shown in Fig. 2. The left upper region corresponding to the tumor site exhibited high optical contrast in rTHC, rHb, and OI. The lower center region corresponds to the nipple showing rTHC and rHb larger, and rStO2 smaller than unity.

3.2.3 Fibroadenoma

The third example is from a 51-year-old premenopausal female with a fibroadenoma in her left breast. DCE-MRI saw asymmetric density exhibiting some enhancement in the lower outer quadrant [as seen in Fig. 4(b) at the left upper side]. However, no suspicious finding was identified by ultrasound or from the digital mammogram. DOT measurements were performed before any core biopsy. The mammographic density of this breast was categorized as scattered fibroglanular density. Needle localization biopsy yielded benign breast tissue with a 5 mm fibroadenoma.

In the reconstructed images (from a slice 4.6 cm away from the source plane) of Fig. 4, distinct optical contrast in the expected region was not found. The compression distance for the DOT measurement was 6.5 cm. Because the optical contrast was not apparent, a spherical region was assigned as a benign lesion in DOT images based on the extent of gadolinium enhancement in the DCE-MR image, which was sub-

Choe et al.: Differentiation of benign and malignant breast tumors by in-vivo three-dimensional parallel-plate...
stantially larger than the size reported by histopathology. Two regions of high OI were notable, but they did not correspond to the fibrosis region identified by MRI.

3.3 Distinction between Benign and Malignant Lesions Based on Optical Tumor Contrast

Figure 5 shows the data for each group, while Table 4 summarizes mean values and 95% confidence intervals for optical contrast parameters (rTHC, rStO2, rHb, rHbO2, OI). A value of 1.0 indicates zero contrast. The benign group exhibited contrast of 0.96–1.11 for all parameters, which was not significantly different from 1.0. With the exception of rStO2, the parameter estimates for the malignant lesions in both MalBcb and MalAcb groups were significantly higher than 1.0. Mean values of rHbO2 and OI were more than 1.5 and 1.8 for both malignant groups. In no case were significant differences found between mean values of the parameters for the MalBcb and MalAcb groups. The intrasubject tissue variability (\(\sigma_Y/Y\)) was calculated based on the standard deviations of both normal (N) and tumor (T) regions, i.e., \(\sigma_Y/Y = \sqrt{(\sigma_X_{TN}/\bar{X}_{TN})^2 + (\sigma_X_{XT}/\bar{X}_{XT})^2}\), where \(Y = \bar{X}_{TN}/\bar{X}_{TN}\). The median intrasubject variability of 51 lesions for rTHC, rStO2, rHbO2, rHb, and rHbO2 were 9, 5, 20, 10, and 14%, respectively. This intrasubject variability for each region was not included in the statistical analysis presented in Table 4, because the focus of the current study was not the automatic detection of the lesion location but rather the characterization.
of lesions, with lesion location provided by other imaging modalities. Menopausal status, race, and size of lesion did not show an association with any of the optical contrast parameters (data not shown). However, BMI was associated ($P < 0.05$) with both $r\mu'_s$ and OI in both univariate models and after adjustment for type of lesion (malignant versus benign). While the effects of BMI were statistically significant for $r\mu'_s$ and OI, they were substantially less than the effects of lesion type (data not shown).

Figure 6 shows the ROC curves for $r\text{THC}$, $r\text{HbO}_2$, $r\mu'_s$, and OI. The ROC curves plot the true positive rate on the vertical axis and the false positive rate on the horizontal axis.

For example, for $r\text{THC}$, if we designated a lesion with $r\text{THC} > 1.06$ as malignant, then 40 out of 41 malignant lesions would be correctly identified for a sensitivity (true positive rate) of 98% ($95\% \text{ CI}=87–100\%$), and 9 out of 10 benign lesions would be correctly identified for a specificity (1−false positive rate) of 90% ($95\% \text{ CI of wide range: 55–100\%}$). Table 5 shows the AUC and OR values for a lesion to be malignant versus benign for each optical parameter. All of the parameters except $r\text{SiO}_2$ and $r\text{Hb}$ were positively associated with increased odds of malignancy, with OR values ranging from 4.3 to 176 per 0.10 (10%) increase in the relative optical parameters. Similarly, the AUCs suggested good discrimina-
tory power with values, excluding rStO2 and rHb, between 0.90 and 0.99. The OR values for rTHC, rHbO2, and OI achieved statistical significance (i.e., \( P < 0.05 \)). However the 95% CIs of ORs were wide. For example, the 95% CI for \( r_{\text{THC}} \) was from 1.4 to 333, the 95% CI for rTHC was from 3.3 to 9432, and the 95% CI for OI was from 1.3 to 33.3. This indicates substantial uncertainty in the parameter estimates and is a result of the relatively small sample size, particularly the small number of benign lesions (\( N=10 \)). Additionally, the performance of any of these predictors would weaken if applied to a new validation dataset, because the predictions are based on a small number of benign lesions.

### Table 4

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Benign (mean 95% CI)</th>
<th>Malignant before core biopsy (mean 95% CI)</th>
<th>Malignant after core biopsy (mean 95% CI)</th>
<th>Biopsy effect</th>
<th>Benign versus Malignant</th>
</tr>
</thead>
<tbody>
<tr>
<td>rTHC</td>
<td>0.98 (0.89–1.09)</td>
<td>0.56 (1.10–1.25)</td>
<td>1.19 (1.10–1.28)</td>
<td>0.45</td>
<td>0.01*</td>
</tr>
<tr>
<td>rStO2</td>
<td>0.94 (0.86–1.08)</td>
<td>0.27 (0.90–1.06)</td>
<td>0.97 (0.90–1.05)</td>
<td>0.71</td>
<td>0.13</td>
</tr>
<tr>
<td>rHbO2</td>
<td>0.94 (0.80–1.11)</td>
<td>0.25 (1.01–1.28)</td>
<td>1.15 (1.03–1.29)</td>
<td>0.79</td>
<td>0.02*</td>
</tr>
<tr>
<td>rHb</td>
<td>0.98 (0.77–1.25)</td>
<td>0.79 (1.28–1.83)</td>
<td>1.53 (1.28–1.84)</td>
<td>1.00</td>
<td>0.005*</td>
</tr>
<tr>
<td>OI</td>
<td>1.04 (0.76–1.41)</td>
<td>0.67 (1.43–2.35)</td>
<td>1.84 (1.43–2.37)</td>
<td>0.96</td>
<td>0.004*</td>
</tr>
</tbody>
</table>

### 4 Discussion

#### 4.1 Significance

Several groups have reported measurable differences in the optically-derived properties of breast tumors compared to background tissues. The research reported herein, however, differs for several reasons, including instru-

- **Fig. 5** rTHC, rStO2, rHb, rHbO2, and OI of all 51 lesions. Lesions are separated into three groups: benign lesions, malignant lesions measured before core-biopsy (MalBcb), and malignant lesions measured after core-biopsy (MalAcb).

- **Fig. 6** Receiver operating characteristic curves for rTHC, rHbO2, \( r_{\mu_s} \), and OI showing true positive rate for malignant lesions versus false positive rate for benign lesions. These rates are calculated by imposing a cutoff value (i.e., numerical values on each curve). For example, if \( r_{\text{THC}}>1.06 \) designates positive result, then true positive rate is 98% and false positive rate is 10%.

- **Table 4** Mean (95% CI) of extracted relative DOT parameters for three different lesion groups and \( P \) values testing three different types of hypotheses. \( P_a \) is the measure for the difference between tumor and normal tissue. \( P_b \) is the measure for the difference between malignant groups measured before (MalBcb) and after core biopsy (MalAcb). \( P_c \) is the measure for the difference between benign and malignant groups. An asterisk indicates that the difference is statistically significant (\( P < 0.05 \)).
Table 5 AUC and OR of lesion being malignant versus benign for a 0.10 (10%) increase in the value of the optical parameter. Asterisks are associated with P<0.05 to indicate statistical significance.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>AUC</th>
<th>OR (95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>rTHC</td>
<td>0.98</td>
<td>176 (3.3–9432)</td>
<td>0.01*</td>
</tr>
<tr>
<td>rSO2</td>
<td>0.57</td>
<td>1.3 (0.5–3.0)</td>
<td>0.61</td>
</tr>
<tr>
<td>rHbO2</td>
<td>0.90</td>
<td>4.3 (1.7–10.7)</td>
<td>0.001*</td>
</tr>
<tr>
<td>rHb</td>
<td>0.66</td>
<td>1.2 (0.9–1.7)</td>
<td>0.27</td>
</tr>
<tr>
<td>μs′</td>
<td>0.99</td>
<td>21.4 (1.4–333)</td>
<td>0.03*</td>
</tr>
<tr>
<td>OI</td>
<td>0.99</td>
<td>6.5 (1.3–33.3)</td>
<td>0.03*</td>
</tr>
</tbody>
</table>

4.3 Relative Measures and the Optical Index

Our focus on tumor-to-normal ratios rather than absolute properties is driven by the observation that intersubject absolute optical property variation is quite significant. For example, averaged over the whole breast, reconstructed THC varied from 6 to 45 μM and reconstructed μs′ at 786 nm from 7 to 13 cm⁻¹. Intersubject variation in absolute optical properties is caused by differences in breast-tissue composition. A significant inverse correlation between THC and BMI has been found, for example, across a wide range of DOT/DOS instrumentation and measurement geometries. Higher BMI is indicative of more adipose tissue content, wherein the blood supply is smaller than in glandular tissue. In contrast to absolute THC, rTHC has emerged from our data as robust quantity for tumor contrast regardless of tissue composition. Similarly, rμs′ has proven superior to absolute μs′ for tumor contrast. Evidently relative contrast can remain, even if absolute optical properties shift. It is also desirable to find other tissue optical indices which improve malignancy contrast. This concept has also been used by Cerussi et al. Our suggested optical index, OI= rTHC×rμs′/rSO2, improved tumor contrast and is a logical composite variable based on the hypothesis of tumor hypermetabolism. It is also less sensitive to absorption-scattering crosstalk.

4.4 Physiological Origins of Optical Tumor Contrast

Angiogenesis associated with solid tumors of radiologically detectable size likely contributes to high THC contrast between breast tumor and normal tissue measured by DOT. DOT is sensitive to vasculature at the microvessel level (i.e., capillaries, arterioles, and venules). Indeed, a positive correlation between microvessel density and THC has been found, providing further insight about the microscopic origin of THC contrast. Among various physiological parameters available to DOT and DOS, most groups have reported the high THC contrast of malignant tumors. The origin of scattering contrast of the cancer is more elusive than absorption. Nevertheless, an increase in number density of subcellular organelles (e.g., mitochondria and nucleolus), due to cell proliferation, can increase tissue scattering. Recently, Li et al. have observed significant differences in the mean size and volume fraction of cellular scattering components (thus scattering coefficients) between
benign and malignant lesions. Some groups have reported tu-
mor scattering contrast comparable to ours, and some have reported contract ~20–40% higher than normal tissue scattering.
Because of absorption and scattering crosstalk issues, at the present time there remains some un-
certainty about the fidelity of the scattering assignment. In our laboratory, we have shown that it is possible to decouple chromo-
phore concentrations and scattering in continuous-wave data by choosing optimal wavelengths. However, our cur-
rent system does not utilize all the optimal wavelengths. Ac-
cording to simulations using the experimental wavelength set, reconstructed $\rho\text{THC}$ was often underestimated, while $\rho\mu'_s$ was often overestimated by 10–20% (data not shown). The overall influence on the optical index was a 10% underestimation. Thus, even though our wavelengths were suboptimal, the re-
resulting parameter crosstalk does not appear to influence the major findings of this study.

Our measurements of $\text{StO}_2$ contrast were not compelling. Cancer oxygen metabolism may depend strongly on the can-
cer stage and biochemical pathways involved. Also, changes in blood oxygenation may be subtle compared to changes in tissue oxygenation induced by tumor hypermetabolism. Indeed, some groups have observed a decrease of $\text{StO}_2$ in the tumor, whereas others observed no difference or even an increase. Images of cancer metabolism have been widely utilized in the positron emission tomography community, wherein breast cancer is frequently characterized by hyperglucose metabolism measured by increased uptake of fluorine-18 fluorodeoxyglucose (18F-FDG). The potential connection between glucose metabolism and oxygen metabolism of cancer may exist; for example, we observed a positive correlation be-
tween the uptake of FDG and $\rho\text{THC}$, $\rho\mu'_s$ and OI using a subset of the present data. Thus far, however, DOT images of tumor oxygen metabolism have not been achieved due to lack of information about blood flow. In the future, DOT plus blood-flow information (derived either by optical means or by another technique) hold potential for imaging of tumor metabolism.

The cysts in our DOT images (not shown) exhibited low $\rho\text{THC}$, $\rho\mu'_s$, and $\text{StO}_2$. This observation is in stark contrast to the high $\rho\text{THC}$, and $\rho\mu'_s$ of the invasive carcinomas. Generally, cysts have been associated with low scattering in DOT images by other groups because the fluid they enclose is optically thin. Sometimes cysts have exhibited lower THC and $\text{StO}_2$ compared to normal tissue as well.

The fibroadenoma in our DOT images showed little or no contrast, as was the case for the lobular carcinoma in situ. Other groups have reported difficulty detecting fibroadenomas. In our analysis, we included lobular carci-
noma in situ in the benign category to be consistent with such recognition in the clinic.

4.5 Core Biopsy Effects

It has been speculated that core biopsy can cause bleeding significant enough to interfere with the hemoglobin-based DOT signal. In some cases, where the bleeding was severe enough to be detected by eye, the corresponding bruise region in the DOT images showed lower blood-oxygen levels compared to the surrounding tissue as well as elevated THC and scattering. Lower $\text{StO}_2$ in this case may be due to a lack of oxygen supply to the noncirculating blood that has permeated into the extracellular space. However, when these parameters were averaged over the population of each group (i.e., malig-
nant group before and after core biopsy), differences between the pre- and postbiopsy groups were not apparent. This obser-
vation indicates that overall variation within each malignant group is more than the variation due to core-biopsy effect. In addition, no correlation between the tumor-to-normal ratios of optical parameters and the number of days after biopsy was found (data not shown). This result could change for DOT data measured less than 1 week after the core biopsy. Clearly, in order to fully understand the effect of core biopsy or fine needle aspiration on the DOT signal, it is desirable to perform a longitudinal study following subjects before and after core biopsy (which is beyond the scope of the present publication).

4.6 Selection of Optimal Parameters to Differentiate Benign and Malignant Lesions

In order to assess which optical parameters among many are useful for differentiating benign and malignant tumors, we employed an ROC curve analysis for each parameter. Because the influence of core biopsy on our DOT data was determined to be negligible (see Sec. 3.3), we combined the two groups into one malignant cancer category and compared the malignant group ($N=41$) with the benign group ($N=10$). The AUC of $\rho\text{THC}$, $\rho\mu'_s$, $r\text{HbO}_2$, and OI suggested good discriminatory power ($<0.90$) to differentiate malignant and benign groups.

ROC curve analysis is important for testing the effective-
ness of any diagnostic imaging method. So far, only a few diffuse optics groups have attempted ROC curve analysis. Chance et al. used a combination of relative THC and $\text{StO}_2$ (derived by DOS) of tumors measured with respect to the contralateral side and obtained 95% AUC to discern cancer from normal tissue. In our case, $r\text{StO}_2$ did not have much discriminatory power. Furthermore, due to our small number of benign cases, any attempt to combine multiple parameters would result in an overfit of the statistical model. Poplack et al. achieved 88% AUC for differentiating cancer from normal tissue and 76% AUC for differentiating malignant cancer from benign lesion distinction using $\rho\text{THC}$ derived from 3-D DOT images for a subset of subjects with lesions larger than 6 mm; their AUC decreased when smaller lesions were in-
cluded in the data set. However, these findings do not repre-
sent a final assessment of DOT performance. Each of these papers focused on demonstrations of particular methodology and were not representative of all or even optimized diffuse optical methods. The discrepancy among groups could be a function of methods (e.g., two parameters versus one param-
ter, localization of tumor with other modalities, etc.) and the variations in the subject groups (e.g., lesion size, percentage of benign and malignant lesions).

4.7 Future Study Design

A key limitation in our study, as well as those published by other groups, is a small sample size, especially of benign le-
sions. The lack of statistical significance in benign tumors arises from two effects: (i) a lack of intrinsic lesion-to-normal contrast in some benign lesions, and (ii) the small sample size. By averaging over different types of benign lesions, distinct
optical signatures of certain lesion types (e.g., cysts) have not been isolated. For future studies, it will be necessary to collect more data (especially benign cases) in order to build a stronger predictive model to differentiate benign and malignant lesions. Also, with more data, it should be possible to find the best combination of multiple parameters for differentiation of malignant and benign lesions, and further differentiation of lesion types (e.g., ductal carcinoma in situ versus invasive ductal carcinoma, and fibroadenoma versus cyst). Furthermore, in the future we can use a large population of lesions without regional averaging (i.e., including the intraregion variability of individual subjects) to develop more advanced analyses that differentiate lesion types and automatically locate lesions in the reconstructed images.

The current instrumentation and analysis scheme is limited because only four lasers were frequency modulated and because this group did not include the 905 nm laser. Thus, it was difficult to directly measure bulk water content. For this reason, we assumed background water and lipid concentrations to be 31 and 57%\text{v/v}, respectively, following previous reports in the literature.\textsuperscript{56-58} As per continuous-wave diffuse optical tomography, we chose not to reconstruct water concentration, because approximately half of the patient data was taken without the 905 nm source. Of course, fixing the water concentration can introduce errors in our estimation of Hb and HbO\textsubscript{2} concentration. To explore the effects of assumed background water concentration on the relative tumor-to-normal ratios, we performed a full reconstruction on selected data set (N=4) with different assumed water concentrations (i.e., at 15, 31, 45, and 60%). These variations in water concentration did not change the overall spatial features of the image (e.g., regions with contrast remained the same). However, extracted rTHC, rStO\textsubscript{2}, r\(\mu\)s, rHb, rHbO\textsubscript{2}, and OI did vary somewhat, differing by 4–7, 3–6, 5–7, 7–10, 6–7, and 6–14%, respectively, from results with 31% water concentration. These variations are less than intersubject variability (95% CI) shown in Table 4.

We will address these hardware limitations with “next generation” DOT instrument.\textsuperscript{96} This instrument will employ light sources at optimal wavelengths, will add water sensitive wavelengths, and will carry out all measurements in the frequency domain. This approach will therefore reduce absorption-scattering crosstalk and will permit reconstruction of water and lipid concentrations. Finally, such new instrumentation should more readily permit separation of the scattering prefactor \(b\) from the scattering power \(\mu\)s. In addition, more light-source positions will permit denser sampling of small breasts. We will use a sophisticated, automated deformation algorithm\textsuperscript{97} to coregister MRI and DOT images taken nonconcurrently. Furthermore, the new system will operate in any of sagittal, craniocaudal, or mediolateral oblique compression, allowing us to better match the clinical imaging geometry and improve our nonconcurrent coregistration. The reconstruction algorithm will be improved to further reduce image artifacts and to employ MRI-derived anatomical information to constrain our DOT reconstruction algorithms.

5 Conclusion

In this paper, we reported diffuse optical tumor-to-normal contrast extracted from 3-D reconstructions of 51 breast tumors using our parallel-plate DOT system. Elevated regions of THC and scattering in malignant cancers in DOT images generally correlated well with tumor regions identified by MRI. By contrast, cysts exhibited lower scattering than the surrounding tissue, and fibroadenomas showed zero or relatively weaker contrast in THC and scattering. The tumor-to-normal ratios in THC, HbO\textsubscript{2}, scattering, and the OI of the malignant cancer group were statistically significant and different from unity, whereas those of the benign tumor group were not. These parameters also exhibited high AUC values for distinguishing between malignant and benign lesions. The effect of core biopsy in our malignant tumor group was not statistically significant when DOT measurement was done more than 1 week after core biopsy. Our results suggest that benign and malignant lesions can be distinguished by quantitative 3-D DOT. This distinction between benign and malignant lesions is important for efforts to increase sensitivity and specificity of overall breast cancer diagnosis and for establishing the reliability of the technology for breast cancer therapy monitoring applications.

Acknowledgments

The authors thank Leonid Zubkov for his help on the instrumentation, Han Y. Ban, Wesley Baker, and David Minkoff for useful discussion, and Yoo Kyung Choe for illustrations. We thank clinical research coordinators who have helped with recruitment and measurements: Monika Grosicka-Kopyra, Kathleen McCarthy Thomas, and Anisa Nayeeem. This research was supported by NIH R01-CA75124, R01-EB002109, K99-CA126187, P41-RR02305, NTR01U54CA105480, and Army DAMD17-00-1-0408.

Appendix

In this section we review the relationship between the measured signal at the CCD and the photon fluence rate at the exit plane of the sample. We also briefly describe the formulation of the objective function used for the inverse problem, including regularization.

Relationship between the fluence rate and the signal detected at the CCD

Consider the schematic of the measurement geometry shown in Fig. 7. A CCD image is obtained for each source position.
and wavelength. Let \( \Phi(\lambda_s, r_s, r) \) denote the fluence rate due to source light originating at \( r_s \) with wavelength \( \lambda_s \). The variable \( r \) denotes position in the sample, including at the exit plane. Furthermore, let \( J(\lambda_s, r, r) \) denote the corresponding photon flux at \( r \) and \( L(\lambda_s, r_s, r, \delta) \) denote the photon radiance \( r \) traveling in the \( \delta \) direction. In the \( P_1 \) approximation of the transport equation,\(^{68,69}\) (i.e., the diffusion approximation),

\[
L(\lambda_s, r, \delta) = (1/4 \pi) \Phi(\lambda_s, r_s, r) + (3/4 \pi) J(\lambda_s, r, r) \cdot \delta.
\]

The signal at the CCD plane is detected at a set of discrete points (pixels) of finite size. We denote the detection position on the CCD as \( r_{d,\text{CCD}} \). The power, \( P \), reaching one of the CCD pixels centered at position \( r_{d,\text{CCD}} \) is explicitly related to \( L(\lambda_s, r_s, r_s, \delta) \), i.e.,

\[
P(\lambda_s, r_s, r_{d,\text{CCD}}) = \int \int d^3r \int d\Omega(\delta)L(\lambda_s, r_s, r, \delta)T_r(\delta)R(\delta, r_{d,\text{CCD}}, \delta).
\]

The angular integral extends over the entire half-space solid angle, and the spatial integral extends over the entire exit plane. Here, \( T_r(\delta) \) is a Fresnel transmission factor at the boundary, assumed independent of \( r \) at the exit plane and \( r_{d,\text{CCD}} \); it accounts for the relative transmission of light emitted from the same point along different directions into the detection system. \( R(\delta, r_{d,\text{CCD}}, \delta) \) is a response function which gives the probability that light emitted from position \( r \) in the \( \delta \) direction landed in the pixel centered at \( r_{d,\text{CCD}} \). We further assume that for each \( r_{d,\text{CCD}} \), this response function is sharply peaked at \( r = r_s \), i.e., the response function has a sharp maximum (less than unity) for a small patch of area \( A \) centered on \( r_s \) in the exit plane, and for \( \delta \) within the numerical aperture of the detection system. The response function is zero otherwise. Typically, \( A \) will be on the order of 0.1 to 1 mm\(^2\), much larger than the CCD pixel area due to the lens demagnification. The maximum value of this response function also decreases as the radial distance (distance between \( r_d \) and the lens axis) increases due to beam vignetting.\(^{100}\)

To evaluate Eq. (1), we use Fick’s law to relate photon fluence rate to photon flux, i.e., \( J(r) = -(D/v) \nabla \Phi(r) \), and we apply the partial current boundary condition for the radiance at the exit plane, i.e., \( \Phi(\delta) = (1 + R_{\text{eff}}) (1 - R_{\text{eff}}) (2/D) (v) \times (\partial \Phi/ \partial y) \).\(^{101}\) Here, \( D \) is the photon diffusion coefficient \( (D \approx 3/1 \mu_s' \) ), \( \mu_s' \) is the reduced scattering coefficient, \( v \) is the velocity of light in the medium, and \( R_{\text{eff}} \) is the effective reflectance at boundary. Evaluating Eq. (1) gives

\[
P(\lambda_s, r_s, r_{d,\text{CCD}}) = \Phi_m(\lambda_s, r_s, r_s)AG(r_s)
\]

Here, we have assumed that the measured fluence rate, \( \Phi_m \), is roughly constant over the patch area \( A \), and we have associated a single \( r_s \) at the exit plane with each \( r_{d,\text{CCD}} \). \( G(r) \) is a geometric factor that includes the Fresnel factor integral over the system numerical aperture and the Vignetting effect. The corresponding CCD readout is \( N(\lambda_s, r_s, r_{d,\text{CCD}}) = \Phi_m(\lambda_s, r_s, r_s)AG(r_s)\nu(\lambda_s)g\Delta t \), where \( \nu(\lambda_s) \) is the quantum efficiency of the detector, \( \Delta t \) is the camera exposure time, and \( g \) accounts for internal amplifier gains in the detection device. Thus, \( N(\lambda_s, r_s, r_{d,\text{CCD}}) \) is proportional to \( \Phi_m(\lambda_s, r_s, r_s) \).

In order to extract tissue optical properties we must compare \( \Phi_m(\lambda_s, r_s, r_d) \) to the calculated fluence rate at the exit plane \( \Phi(\lambda_s, r_s, r_d) \) based on the optical property distribution in the sample. We compute \( \Phi(\lambda_s, r_s, r_d) \) using a finite-element-method-based numerical solver\(^{68}\) wherein we employ a nonuniform unstructured mesh with higher nodal concentrations at source/detector planes in order to increase the forward model accuracy and suppress image artifacts associated with sources and detectors.\(^{69}\) We model our reconstruction volume to mimic the physical boundary system of the breast box and also the breast and Intralipid interfaces. The effective reflectance coefficient, \( R_{\text{eff}} \), at the boundary is estimated based on the ratio between the refractive index of the sample medium \( n \) and the outside medium \( n_{\text{out}} \).\(^{102}\) At \( y = L_s \), we have a glass window (with antireflection coating on the opposite side of the exit plane) which we model as a tissue–glass interface (i.e., \( n = 1.4 \) and \( n_{\text{out}} = 1.5 \)). The \( z = 0 \) boundary is modeled as a tissue–air boundary (i.e., \( n = 1.4 \) and \( n_{\text{out}} = 1.0 \)). The rest of the black-coated boundaries are modeled as having total absorption \( (R_{\text{eff}} = 0) \). Note that our reconstruction volume in the \( z \) direction extends upward to account for the presence of the chest.

**Objective Function**

The objective function, \( \chi^2 \), is a measure of the difference between \( \Phi_m \) and \( \Phi_c \), summed over all the measurements. In our case, we modify a Rytov-type objective function for the multispectral method by summing over all source–detector position pairs and all wavelengths. The detailed form of \( \chi^2 \) is as follows:

\[
\chi^2 = \frac{1}{2} \sum_{i=1}^{N_s} \sum_{j=1}^{N_t} \sum_{d=1}^{N_d} \left[ \Phi_m(\lambda_s, r_s, r_d) - \Phi_c(\lambda_s, r_s, r_d) \right]^2 + Q.
\]

Here, the image norm \( Q = \sum_{i=1}^{N_s} \gamma(r_s) ||\mu(r_s) - \mu_0(r_s)||^2 \), where \( N_s \) is the total number of voxels. \( \mu_s \) stands for solution vector (i.e., \( \mu_0 \) and \( D \)) and the superscript 0 refers to the value of \( \mu(r_s) \) in the previous iteration. In the multispectral approach, \( \mu \) is computed based on the chromophore concentrations, \( C \), via the relation \( \mu_\lambda = \sum_{i=1}^{N_s} \epsilon_i(\lambda) C_i + \mu_\lambda^0(\lambda) \), where the scattering factors \( A \) and \( b \) are related via the relation \( \mu_\lambda^0(\lambda) = A \lambda^{-b} \). \( N_s, N_t, \) and \( N_d \) are the number of wavelengths, sources, and detectors, respectively. The superscript \( R \) refers to quantities (i.e., \( \Phi_m, \Phi_c \), or \( N \)) derived from the homogeneous Intralipid/Ink reference sample. We were able to use our CCD readings, \( N \) and \( N_R \), directly in place of \( \Phi_m \) and \( \Phi_c \) because the proportionality constants are assumed identical between the breast and Intralipid/Ink measurements (i.e., the constants
cancel one another. The normalization with the Intralipid/Ink measurement is important for the integrity of our reconstruction, because it minimizes systematic errors that may be present in our measurement, including the lens Vignetting effect, and source strength fluctuations among different source positions, etc. 

\[ \gamma(r_s) = \begin{cases} 
\exp \left(-\frac{x-x_{\min}}{L_x}\right)^2 + \exp \left(-\frac{y-y_{\min}}{L_y}\right)^2 + \exp \left(-\frac{z-z_{\min}}{L_z}\right)^2 
\end{cases} \]

(5)

Here, \( \alpha \) is the regularization parameter and \( L_x, L_y, L_z \) are the dimensions of the sample box. \( x_{\min}, y_{\min}, z_{\min} \) and \( x_{\max}, y_{\max}, z_{\max} \) are minimum and maximum coordinates of the sample box, respectively. \( y \) is the axis perpendicular to the source and detection planes. For \( L \)-curve analysis, we varied \( \alpha \) as described in the text (Section 2.3). We use the nonlinear conjugate gradient method to minimize \( \chi^2 \), computing the search direction based on the gradient of \( \chi^2 \). This method does not require a matrix inversion for computing search directions. Therefore, it is especially useful for systems with a large number of source–detector pairs and large reconstruction domains wherein building and inverting the Jacobian matrix can be computationally difficult and even impossible due to memory limitations.

References


Choe et al.: Differentiation of benign and malignant breast tumors by in-vivo three-dimensional parallel-plate...